Version 1
: Received: 13 July 2023 / Approved: 14 July 2023 / Online: 14 July 2023 (08:47:26 CEST)
How to cite:
Aitken, J.M.; Aitken, J.E.; Agrawal, G. Mycobacterium avium ssp. Paratuberculosis and Crohn’s Disease—Time to Consider New Therapeutic Approaches?. Preprints2023, 2023070994. https://doi.org/10.20944/preprints202307.0994.v1
Aitken, J.M.; Aitken, J.E.; Agrawal, G. Mycobacterium avium ssp. Paratuberculosis and Crohn’s Disease—Time to Consider New Therapeutic Approaches?. Preprints 2023, 2023070994. https://doi.org/10.20944/preprints202307.0994.v1
Aitken, J.M.; Aitken, J.E.; Agrawal, G. Mycobacterium avium ssp. Paratuberculosis and Crohn’s Disease—Time to Consider New Therapeutic Approaches?. Preprints2023, 2023070994. https://doi.org/10.20944/preprints202307.0994.v1
APA Style
Aitken, J.M., Aitken, J.E., & Agrawal, G. (2023). Mycobacterium avium ssp. Paratuberculosis and Crohn’s Disease—Time to Consider New Therapeutic Approaches?. Preprints. https://doi.org/10.20944/preprints202307.0994.v1
Chicago/Turabian Style
Aitken, J.M., Jack E Aitken and Gaurav Agrawal. 2023 "Mycobacterium avium ssp. Paratuberculosis and Crohn’s Disease—Time to Consider New Therapeutic Approaches?" Preprints. https://doi.org/10.20944/preprints202307.0994.v1
Abstract
Mycobacterium avium ssp paratuberculosis (MAP) is the causative agent of Johne’s disease (JD) in animals and a suspected cause of Crohn’s disease (CD) in humans. Crohn’s Disease is a progressive, detrimental granulomatous enteritis of which common therapies are targeted to suppressing certain components of the immune system. The efficacy of these treatments can be variable and temporary with no clear process of selection for the individual patient. However, diagnosis of MAP has been elusive in patients with Crohn’s Disease. In animals it can be detected by several different techniques, including bacterial cell culture, polymerase chain reaction (PCR), and immunological targets. To move to an understanding of the possible pathogenicity of MAP and the sup-posed cause of CD in humans, it is necessary to demonstrate the presence of cell wall deficient mycobacterial (CWDM) forms of MAP in blood and tissue cultures from patients with CD. From this, more tailored and accurate therapies can be implemented and be developed to eradicate this infectious organism from humans. Current anti-mycobacterial antibiotics have limited efficacy as MAP is subtly different from tuberculosis. Newer methods, such as vaccination and gut microbiome remediation will be essential as part of combination therapies.
Medicine and Pharmacology, Gastroenterology and Hepatology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
